12/27
09:38 am
virx
ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls [Yahoo! Finance]
High
Report
ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls [Yahoo! Finance]
12/27
08:11 am
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.
High
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.
12/26
04:33 pm
virx
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives [Yahoo! Finance]
High
Report
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives [Yahoo! Finance]
12/26
04:30 pm
virx
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
High
Report
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
11/14
01:35 pm
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.
Medium
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.
11/13
07:00 am
virx
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
04:43 pm
virx
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma [Yahoo! Finance]
High
Report
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma [Yahoo! Finance]
11/6
04:30 pm
virx
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
Medium
Report
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
10/22
09:59 am
virx
Post-Transplant Lymphoproliferative Disorder Drug Pipeline Market Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Low
Report
Post-Transplant Lymphoproliferative Disorder Drug Pipeline Market Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]